GKSL173.89

Gujarat Kidney And Super Speciality Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersGPTHEALTHSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,371 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations28.223.230.634.3
Other Income0.10.10.70.7
Total Income28.323.331.335.0
Expenses
+ Cost of Materials Consumed2.73.13.44.3
+ Employee Benefit Expense4.34.05.35.3
+ Finance Costs0.50.60.80.7
+ Depreciation & Amortisation1.91.31.51.4
+ Other Expenses7.49.315.616.3
Total Expenses16.818.326.628.0
EBITDA13.76.96.38.4
EBIT11.95.64.86.9
Profit
PBT before Exceptional Items11.55.04.77.0
Pretax Income11.55.04.77.0
+ Current Tax3.31.40.51.8
+ Deferred Tax-0.1-0.1-0.6-0.1
Tax Expense3.21.3-0.11.6
Net Income8.33.74.85.3
+ Net Income — Continuing Ops8.33.74.85.3
+ Other Comprehensive Income0.00.0-0.10.2
Total Comprehensive Income8.33.74.75.5
Net Income to Common7.52.95.05.2
Minority Interest0.80.80.20.1
Per Share
Basic EPS1.470.520.810.66
Diluted EPS1.470.520.810.66
Other Comprehensive Income — detail
+ Other Comprehensive Income0.00.0-0.10.2
+ Items NOT to be Reclassified to P&L0.1-0.00.3
+ Tax on Items NOT to be Reclassified0.0-0.00.10.1
+ Tax on Items to be Reclassified0.00.00.0
Comprehensive Income — Owners of Parent7.63.0-0.10.2
Comprehensive Income — Non-controlling Interests0.80.80.0-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations1.470.520.810.66
Diluted EPS — Continuing Operations1.470.520.810.66
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit25.520.227.229.9
Gross Margin %90.4586.8788.9887.34
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)11.55.04.77.0
Net Income Adj (tax-effected)8.33.74.85.3
EPS Adj1.470.520.810.66
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Filed Debt Equity0.000.00
Filed Iscr0.000.07
Paid Up Equity Capital5,68,435.07,88,432.515.815.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.